Integra LifeSciences (NASDAQ:IART) Trading Up 6.2% After Analyst Upgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART) was up 6.2% during trading on Thursday after Truist Financial raised their price target on the stock from $14.00 to $19.00. Truist Financial currently has a hold rating on the stock. Integra LifeSciences traded as high as $20.00 and last traded at $19.9350. 97,377 shares changed hands during trading, a decline of 89% from the average daily volume of 888,973 shares. The stock had previously closed at $18.78.

IART has been the subject of a number of other reports. Wells Fargo & Company increased their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Citigroup restated a “neutral” rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a report on Thursday, June 18th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $18.33.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds have recently modified their holdings of the stock. Global Retirement Partners LLC bought a new position in shares of Integra LifeSciences during the fourth quarter worth $25,000. Osaic Holdings Inc. increased its holdings in Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares during the last quarter. GAMMA Investing LLC increased its holdings in Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Integra LifeSciences in the 4th quarter worth $124,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

The firm’s fifty day simple moving average is $16.91 and its 200 day simple moving average is $13.08. The firm has a market cap of $1.50 billion, a P/E ratio of -2.98, a P/E/G ratio of 1.37 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. During the same quarter last year, the business posted $0.41 earnings per share. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.